Previous close | 1,980.00 |
Open | 2,051.48 |
Bid | 2,031.50 x 0 |
Ask | 0.00 x 0 |
Day's range | 2,051.48 - 2,051.48 |
52-week range | 1,380.00 - 2,318.97 |
Volume | |
Avg. volume | 21 |
Market cap | 815.841B |
Beta (5Y monthly) | 1.16 |
PE ratio (TTM) | 73.53 |
EPS (TTM) | 27.90 |
Earnings date | 25 Jul 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Dexcom (DXCM) and Abbott are set to launch their first FDA-approved over-the-counter CGMs, Stelo and Lingo & Libre Rio, respectively, in the United States this summer.
Key Insights Using the 2 Stage Free Cash Flow to Equity, DexCom fair value estimate is US$113 DexCom's US$113 share...
Smart rings and smartwatches are providing consumers with reams of health information. Clinical device makers like DexCom needn’t worry.